Phaseline

Companies › Applied Biologics

Applied Biologics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 4, 1 Phase 3; Metabolic and endocrine, Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XPURT
Single-layer amniotic membrane
–Phase 4Pressure UlcerAug 2027
XWRAP
Single layer placental-based allograft
–Phase 4Diabetic FootAug 2027
BIOxHEAL
human amniotic membrane allograft
–Phase 3Diabetic Foot UlcerSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07159282XWRAPPhase 4Diabetic FootMetabolic and endocrineAug 2027
NCT07126886XPURTPhase 4Pressure UlcerImmunologyAug 2027
NCT07852338BIOxHEALPhase 3Diabetic Foot UlcerMetabolic and endocrineSep 2027

From the company's SEC filings

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Sequence LifeScience Tiger Biosciences BioLab Holdings Yong Zhao, MD, PhD Spur Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.